Sunitinib and sorafenib treatment also upregulates the expression of NKG2D and induces sensitivity of NK cells to tumor cells (Y. Huang, Wang, Li, Guo, & He, 2011; Y. X. Huang et al., 2017). This evidence concerns the gene KLRK1 and neoplasm.